Solid says early data suggest ‘differentiated’ Duchenne gene therapy

cafead

Administrator
Staff member
  • cafead   Feb 18, 2025 at 11:22: PM
via The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.

article source